Expression of Interest

Contact Person/Scientist in Charge

  • Name and surname: Ismael Galve-Roperh
  • Email: igrSPAMFILTER@quim.ucm.es

Universidad Complutense de Madrid

Department / Institute / Centre

  • Name: Universidad Complutense de Madrid / Faculty of Chemical Science
  • Address: Avda. Complutense, s/n; Ciudad Universitaria; 28040 - MADRID
  • Province: Madrid

Research Area

  • Life Sciences (LIF)

Brief description of the institution:

Universidad Complutense de Madrid (UCM) is a broad-scoped university -the largest in Spain- in which almost every field of knowledge is envisaged. Due to this broad-scoped nature UCM is able to offer 170 official degrees out of which 65 correspond to bachelor degrees and 105 to master degrees. Regarding research activities they are developed through its 21 faculties, 5 university schools, 9 associated centers, 40 university research institutes, 8 schools for professional specialization, 4 university hospitals, and 17 research assistance centers. All these centers host nowadays almost 600 research groups.

Brief description of the Centre/Research Group (including URL if applicable):

The “Cannabinoid and Neurogenesis” group is part of the Dept of Biochemistry and Molecular Biology I (Complutense University) and member of the CIBERNED consortium for research on neurodegenerative diseases. Our group is devoted to the study of neural cell fate regulation by cannabinoid signaling. We investigate the pathophysiological functions of the endocannabinoid system, as well as the consequences of plant-derived cannabinoid exposure in the different research lines detailed below. Our experimental approaches includes the use of a variety of experimental models ranging from in vitro studies using neural and stem cell cultures, signal transduction research, genetic (conditional loss and gain of function) and pharmacological regulation of in vivo mouse models (reporters and conditional/constitutive deficient mice). Translational implications of our research findings are explored in close collaboration with our clinicians collaborators involved in refractory epilepsy and Huntington’s disease. The “Cannabinoid and neurogenesis” group in the last 15 years has contributed to define the neurodevelopmental role of cannabinoid signaling with seminal publications that highlighted the requirement of an appropriate endocannabinoid tone in neural progenitor proliferation, neuronal differentiation and long-range axon projection.

Project description:

The following research lines are active in the group. The latest publication related to each one is included as example.

 - Cannabinoid signaling in neural stem cells and progenitor identity.

 (Díaz-Alonso et al. CB1 Cannabinoid Receptor-Dependent Activation of mTORC1/Pax6 Signaling Drives Tbr2 Expression and Basal Progenitor Expansion in the Developing Mouse Cortex. Cereb Cortex. 25:2395-408 (2014).

 - Neurodevelopmental alterations induced by prenatal cannabinoid exposure.

 (de Salas-Quiroga et al., Prenatal exposure to cannabinoids evokes long-lasting functional alterations by targeting CB1 receptors on developing cortical neurons. Proc Natl Acad Sci USA 112:13693-8 (2015)

 - Involvement of the endocannabinoid system in malformations of cortical development and refractory epilepsy.

 (Díaz-Alonso et al., Loss of cannabinoid CB1 receptors induces cortical migration malformations and increases seizure susceptibility. Cerebral Cortex doi: 10.1093/cercor/bhw309 (2016).

 - The endocannabinoid system in adult neurogenesis.

 (Campos et al., The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacology 9:1-13 (2013).

 - Neuroprotection based in cannabinoid-derived drugs.

 (Blázquez et al., The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death and Differentiation 22:1618-29 (2015).

 Diaz-Alonso et al., VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington’s disease. Scientific Reports 19 ;6:29789 (2016).

Applications

- CV including academic, scientific and professional achievements

- Letter of interest

- Contact information of previous supervisors for reference purposes

Application deadline: 2018-07-15

I want to contact the Institution

De acuerdo a lo establecido en el artículo 5 de la Ley Orgánica 15/1999, de 13 de diciembre, de Protección de Datos de Carácter Personal, queremos informarle que sus datos serán incluidos en un fichero del que es titular la Fundación Española para la Ciencia y la Tecnología, y que tiene por finalidad la gestión de servicios de FECYT a la comunidad científica y tecnológica y a la sociedad. Si usted aporta datos de carácter personal de terceros, se compromete a solicitarles su consentimiento inequívoco para ello, de conformidad con lo dispuesto en el artículo 6 de la LOPD.

En el caso en el que acepte ser informado de otras actividades, novedades, productos o servicios relacionados con FECYT queremos informarle que sus datos serán incluidos en un fichero del que es titular la Fundación Española para la Ciencia y la Tecnología, y que tiene por finalidad realizar comunicaciones de carácter institucional general y control documental.

Asimismo, se le informa que puede ejercitar sus derechos de acceso, rectificación, cancelación y oposición en los términos descritos en la L.O.P.D., dirigiéndose a la sede de la Fundación Española para la Ciencia y la Tecnología, sita en C/ Pintor Velázquez nº 5 - Edificio Museo Nacional de Ciencia y Tecnología, 28100 Alcobendas (Madrid).

Compartir en:
  • compartir en twitter
  • compartir en linkedin
  • compartir en facebook
  • compartir en google +